Canaccord Genuity Maintains a 'Buy' on St. Marys (SM); Top Mid-Cap Pick for 2012
Tweet
Share
E-mailGet Alerts SM Hot Sheet
Price: $37.64 +4.15%
Rating Summary:
23 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
23 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on St. Marys (NYSE: SM) price target of $128.00.
Analyst, John Gerdes, said, "SM represents our top mid-cap pick for ’12. We believe Eagle Ford productivity should be more fully appreciated by the Q1 reporting cycle after the completion of a significant Eagle Ford midstream expansion in late ’11. SM offers ~20% more upside potential than the sector in our view, as the stock trades at a ~10% discount (’12E EBITDA) though offers ~70% greater CFPS growth (’11-’13E)."
For an analyst ratings summary and ratings history on St. Marys click here. For more ratings news on St. Marys click here.
Shares of St. Marys closed at $72.87 yesterday.
Analyst, John Gerdes, said, "SM represents our top mid-cap pick for ’12. We believe Eagle Ford productivity should be more fully appreciated by the Q1 reporting cycle after the completion of a significant Eagle Ford midstream expansion in late ’11. SM offers ~20% more upside potential than the sector in our view, as the stock trades at a ~10% discount (’12E EBITDA) though offers ~70% greater CFPS growth (’11-’13E)."
For an analyst ratings summary and ratings history on St. Marys click here. For more ratings news on St. Marys click here.
Shares of St. Marys closed at $72.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold
- Okta, Inc (OKTA) PT Raised to $170 at Cantor Fitzgerald Ahead of Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
